Parallax Volatility Advisers
VTGN icon

Parallax Volatility Advisers’s VistaGen Therapeutics VTGN Stock Holding History

Parallax Volatility Advisers’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-57
Closed -$175 – 3237
2022
Q4 		$175 Sell
57
-10,486
-99% -$39.5K ﹤0.01% 2787
2022
Q3 		$48K Buy
+10,543
New +$104K ﹤0.01% 2624

Other funds holding VTGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parallax Volatility Advisers's VTGN Position: Q2 2023 in Review

Parallax Volatility Advisers sold out of VistaGen Therapeutics (VTGN) in Q2 2023, closing a stake of 3,504 shares — an estimated $13.1K sold.

Parallax Volatility Advisers first reported a position in VTGN in Q2 2016 and held it in 28 quarters. The position peaked at $1.24M in Q3 2016. 33 funds tracked by Wall St. Rank hold VTGN as of Q2 2023.

  • Parallax Volatility Advisers reported no remaining VistaGen Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Parallax Volatility Advisers sold 3,504 VistaGen Therapeutics shares in Q2 2023, an estimated $13.1K.
  • Parallax Volatility Advisers first reported a position in VistaGen Therapeutics in Q2 2016 and held it in 28 quarters.
  • Parallax Volatility Advisers's VistaGen Therapeutics position peaked at $1.24M in Q3 2016.
  • 33 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2023.

Based on Parallax Volatility Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.